Nasdaq

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Business Wire

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced new preclinical data highlighting the company ...
Nasdaq

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...
Business Wire

VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind ...